PE20141005A1 - 1,3-oxazinas como inhibidores de bace1 y/o bace2 - Google Patents
1,3-oxazinas como inhibidores de bace1 y/o bace2Info
- Publication number
- PE20141005A1 PE20141005A1 PE2013002497A PE2013002497A PE20141005A1 PE 20141005 A1 PE20141005 A1 PE 20141005A1 PE 2013002497 A PE2013002497 A PE 2013002497A PE 2013002497 A PE2013002497 A PE 2013002497A PE 20141005 A1 PE20141005 A1 PE 20141005A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- fluor
- bace2
- bace1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 1,3-OXAZINA DE FORMULA (I) DONDE X ES ARILO, HETEROARILO O CICLOALQUILO(C3-C6) OPCIONALMENTE SUSTITUIDOS; Y ES -C=O-NH-, -CH2-, -NH-, ENTRE OTROS; Z ES ARILO, HETEROARILO, CICLOALQUILO(C3-C6), ENTRE OTROS; R2 ES H, ALQUILO(C1-C6) O HALOGENO-ALQUILO(C1-C3); R3 Y R4 SON CADA UNO H, HALOGENO O ALQUILO(C1-C6); R5 Y R6 SON CADA UNO H O ALQUILO(C1-C6). SON COMPUESTOS PREFERIDOS: (S)-4-{5-[(4-CLORO-1-DIFLUORMETIL-1H-PIRAZOL-3-ILMETIL)-AMINO]-2-FLUOR-FENIL}-4-METIL-5,6-DIHIDRO-4H-[1,3]OXAZIN-2-ILAMINA; (4R,5R)-5-FLUOR-4-[2-FLUOR-5-(2-METOXI-FENILAMINO)-FENIL]-4-METIL-5,6-DIHIDRO-4H-[1,3]OXAZIN-2-ILAMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE OBTENCION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE BACE1 Y BACE2 SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, DIABETES TIPO 2
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11166208 | 2011-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141005A1 true PE20141005A1 (es) | 2014-08-27 |
Family
ID=46125426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013002497A PE20141005A1 (es) | 2011-05-16 | 2012-05-11 | 1,3-oxazinas como inhibidores de bace1 y/o bace2 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8785436B2 (es) |
EP (1) | EP2709992A1 (es) |
JP (1) | JP2014513702A (es) |
KR (1) | KR20140041538A (es) |
CN (1) | CN103534243A (es) |
AU (1) | AU2012257834A1 (es) |
CA (1) | CA2832384A1 (es) |
CL (1) | CL2013003262A1 (es) |
CO (1) | CO6801766A2 (es) |
CR (1) | CR20130487A (es) |
EA (1) | EA201391670A1 (es) |
EC (1) | ECSP13013024A (es) |
IL (1) | IL229072A0 (es) |
MA (1) | MA35246B1 (es) |
MX (1) | MX2013013328A (es) |
PE (1) | PE20141005A1 (es) |
SG (1) | SG194848A1 (es) |
WO (1) | WO2012156284A1 (es) |
ZA (1) | ZA201308400B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101052122B1 (ko) | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
JP5383483B2 (ja) * | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
US8637504B2 (en) * | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
WO2010047372A1 (ja) * | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Bace1阻害活性を有する2-アミノピリミジン-4-オンおよび2-アミノピリジン誘導体 |
US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
EP2511268B2 (en) | 2009-12-11 | 2021-02-17 | Shionogi & Co., Ltd. | Oxazine derivative |
JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
CN103261199A (zh) | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
US9242943B2 (en) * | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
US8399459B2 (en) * | 2011-02-02 | 2013-03-19 | Hoffmann-La Roche Inc. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するbace1阻害剤 |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
WO2014010748A1 (en) * | 2012-07-10 | 2014-01-16 | Shionogi & Co., Ltd. | Cyclopropane derivative having bace1 inhibiting activity |
US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
KR20150109429A (ko) * | 2013-01-22 | 2015-10-01 | 시에나 바이오테크 에스.피.에이. | Bace1 억제제로서의 플루오로-[1,3]옥사진 |
JP6389830B2 (ja) * | 2013-03-01 | 2018-09-12 | アムジエン・インコーポレーテツド | ベータ−セクレターゼ阻害剤としてのパーフルオロ化5,6−ジヒドロ−4h−1,3−オキサジン−2−アミン化合物および使用方法 |
US9085576B2 (en) | 2013-03-08 | 2015-07-21 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
MY174747A (en) | 2013-04-11 | 2020-05-13 | Hoffmann La Roche | Bace1 inhibitors |
JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
WO2015132141A1 (en) * | 2014-03-03 | 2015-09-11 | F. Hoffmann-La Roche Ag | 1,3-oxazine-2-amine derivatives acting as bace inhibitors for the treatment of alzheimer's disease |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
WO2016001266A1 (en) | 2014-07-04 | 2016-01-07 | F. Hoffmann-La Roche Ag | Fluoro-[1,3]oxazines as bace1 inhibitors |
WO2016012384A1 (en) | 2014-07-22 | 2016-01-28 | F. Hoffmann-La Roche Ag | Trifluormethyloxazine amidines as bace1 inhibitors |
WO2016022724A1 (en) | 2014-08-08 | 2016-02-11 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
CN105566179B (zh) * | 2014-10-14 | 2017-09-05 | 上海工程技术大学 | 一种制备手性α‑氟‑β‑氨基酸衍生物的方法 |
PE20171349A1 (es) | 2015-03-20 | 2017-09-13 | Hoffmann La Roche | Inhibidores de bace1 |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
TW201726651A (zh) | 2015-09-23 | 2017-08-01 | 健生藥品公司 | 2,3,4,5-四氫吡啶-6-胺衍生物 |
JP6634147B2 (ja) * | 2016-02-25 | 2020-01-22 | 株式会社日本触媒 | オキソカーボン系化合物、樹脂組成物およびインク組成物 |
EP3423450B1 (en) * | 2016-03-01 | 2019-11-27 | H. Hoffnabb-La Roche Ag | Bace 1 inhibitors |
CN107304176A (zh) * | 2016-04-21 | 2017-10-31 | 上海工程技术大学 | α-芳基取代的α-氟代β-氨基酸类化合物及其制备方法 |
MX2019007104A (es) | 2016-12-15 | 2019-11-05 | Amgen Inc | Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso. |
WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
EP3555106B1 (en) | 2016-12-15 | 2022-03-09 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
CA3047288A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
MA52722A (fr) | 2016-12-15 | 2021-04-14 | Amgen Inc | Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
CN107892697B (zh) | 2016-12-26 | 2020-11-03 | 郑州泰基鸿诺医药股份有限公司 | 一种[1,3]噻嗪-2-胺类化合物及应用,药物组合物 |
JP7353708B2 (ja) | 2018-04-27 | 2023-10-02 | 塩野義製薬株式会社 | 選択的bace1阻害活性を有するテトラヒドロピラノオキサジン誘導体 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2520804A1 (en) | 2003-04-03 | 2004-10-28 | Merck & Co., Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
KR101052122B1 (ko) | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
WO2007135026A2 (de) | 2006-05-24 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Substituierte pteridine als therapeutika |
US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
CN102686584A (zh) * | 2009-11-13 | 2012-09-19 | 盐野义制药株式会社 | 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物 |
US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
EP2511268B2 (en) * | 2009-12-11 | 2021-02-17 | Shionogi & Co., Ltd. | Oxazine derivative |
UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
-
2012
- 2012-05-09 US US13/467,085 patent/US8785436B2/en not_active Expired - Fee Related
- 2012-05-11 WO PCT/EP2012/058707 patent/WO2012156284A1/en active Application Filing
- 2012-05-11 JP JP2014510743A patent/JP2014513702A/ja active Pending
- 2012-05-11 EP EP12722112.5A patent/EP2709992A1/en not_active Withdrawn
- 2012-05-11 PE PE2013002497A patent/PE20141005A1/es not_active Application Discontinuation
- 2012-05-11 EA EA201391670A patent/EA201391670A1/ru unknown
- 2012-05-11 KR KR1020137032852A patent/KR20140041538A/ko not_active Application Discontinuation
- 2012-05-11 SG SG2013082755A patent/SG194848A1/en unknown
- 2012-05-11 MX MX2013013328A patent/MX2013013328A/es not_active Application Discontinuation
- 2012-05-11 AU AU2012257834A patent/AU2012257834A1/en not_active Abandoned
- 2012-05-11 CN CN201280023734.0A patent/CN103534243A/zh active Pending
- 2012-05-11 CA CA2832384A patent/CA2832384A1/en not_active Abandoned
-
2013
- 2013-09-26 CR CR20130487A patent/CR20130487A/es unknown
- 2013-10-24 IL IL229072A patent/IL229072A0/en unknown
- 2013-10-31 CO CO13258872A patent/CO6801766A2/es not_active Application Discontinuation
- 2013-11-07 ZA ZA2013/08400A patent/ZA201308400B/en unknown
- 2013-11-14 CL CL2013003262A patent/CL2013003262A1/es unknown
- 2013-11-15 EC ECSP13013024 patent/ECSP13013024A/es unknown
- 2013-12-06 MA MA36536A patent/MA35246B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2012156284A1 (en) | 2012-11-22 |
CN103534243A (zh) | 2014-01-22 |
JP2014513702A (ja) | 2014-06-05 |
CR20130487A (es) | 2013-12-09 |
EP2709992A1 (en) | 2014-03-26 |
ECSP13013024A (es) | 2014-01-31 |
US20120295900A1 (en) | 2012-11-22 |
CA2832384A1 (en) | 2012-11-22 |
US8785436B2 (en) | 2014-07-22 |
SG194848A1 (en) | 2013-12-30 |
CL2013003262A1 (es) | 2014-08-08 |
KR20140041538A (ko) | 2014-04-04 |
NZ616099A (en) | 2014-11-28 |
AU2012257834A1 (en) | 2013-10-17 |
ZA201308400B (en) | 2014-07-30 |
EA201391670A1 (ru) | 2014-03-31 |
IL229072A0 (en) | 2013-12-31 |
MX2013013328A (es) | 2014-01-08 |
MA35246B1 (fr) | 2014-07-03 |
CO6801766A2 (es) | 2013-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141005A1 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
PE20141120A1 (es) | Compuestos heterociclicos | |
PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20121440A1 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos | |
PE20121480A1 (es) | Aminopirimidinas como inhibidores de syk | |
PE20120081A1 (es) | Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton | |
AR055563A1 (es) | Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente | |
PE20110196A1 (es) | 5-alquinil-pirimidinas | |
PE20150021A1 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 | |
PE20161372A1 (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
PE20091816A1 (es) | Inhibidores de bace | |
PE20142376A1 (es) | Fluormetil-5,6-dihidro-4h-[1,3]oxazinas | |
PE20120937A1 (es) | Compuestos derivados de quinolina y quinoxalina como agentes antivirales | |
PE20130647A1 (es) | Indoles | |
PE20121431A1 (es) | Derivados de pirimidina como inhbidores de la enzima cinasa ptk2 | |
PE20110924A1 (es) | Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3 | |
PE20091492A1 (es) | Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr | |
PE20142164A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
PE20120690A1 (es) | Derivados de 5-fluoropirimidinona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |